Ocugen, Inc (OCGN) Stock Price Continue to Stumble Amidst IP Uncertainty


Ocugen, Inc. (OCGN) stock prices were down 6.02% as of market close on April 16th, 2021, settling in at USD$5.78. Subsequent pre-market fluctuation saw a dip to USD$5.30, a drop of 7.09%.

25-cent Stock Takes $11T Commodities Sector Digital

One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.

All the details are in the FREE online report you can get here.


Ocugen and Bharat Biotech Collaborate

In December of 2020, Ocugen announced its collaboration with the India-based Bharat Biotech to facilitate the development of Covaxin, a vaccine for the COVID-19 pandemic that has taken the world by storm. Already having been authorized for use in India, Covaxin is setting the stage for its entry into the U.S. market.

Entering the U.S. Market

With an efficacy rate of 81% according to the results from a late-stage study, Ocugen is hoping to receive Emergency Use Authorization from the U.S. regulatory authorities, with whom it is currently working with. Should they be granted approval, Ocugen will receive 45% of the profits from Covaxin sales in the U.S.

Hope for U.S. Distribution

While there are competing vaccines that have already entered the U.S. market and boast a higher efficacy rate, the sheer demand for COVID vaccines suggests Covaxin could still capitalize on its potential U.S. presence. This is especially the case since the U.S. government halted the distribution of the COVID vaccine developed by Johnson & Johnson.

Covaxin in India

Given how the world is working towards universal immunization as a means to end the ongoing pandemic, all eyes are on producers of various vaccines for COVID. Covaxin comprises 4 million monthly doses of the cumulative 64 million doses being manufactured in India on a monthly basis. To effectively curb the pandemic through comprehensive vaccinations, sustained production of vaccines is absolutely essential for at least the next several months.

Bureaucratic Red Tape

With the patenting of vaccines conflicting with the need to urgently vaccinate entire populations, there are increasing calls for the WTO to temporarily waive intellectual property rights for COVID-19 vaccines. In 2020, India and South Africa argued for the need to waive certain provisions of the Trade-Related Aspects of Intellectual Property Right (TRIPS) agreement.

Call to Waive TRIPS Agreement

This joint proposal has gained steam since then, with more developing countries opting to co-sponsor the joint proposal. There are indications that the World Trade Organisation’s General Council will convene on May 5th of 2021 to discuss this proposal. On April 16th, 2021, U.S. President Biden was urged by a team of Democratic Senators, headed by Bernie Sanders, to support the proposal to temporarily waive intellectual property barriers that were impeding a resolution to this pandemic.

What does this Mean for Ocugen?

Should this proposal go through, it could be financially subversive for the companies that have developed and patented their COVID vaccines. In ordinary circumstances, the development of a new drug grants the producing company 20 years of security through patenting. With that security in question, some shareholders are having reservations about the profitability of Ocugen over the course of the foreseeable future.


Please enter your comment!
Please enter your name here